Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 8/20 | 1.00 |
| ▸ | SOS1 | Q07889 | 6/20 | 0.50 |
| ▸ | KRAS | P01116 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | TACR2 | P21452 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710121 | 1.00 | SMYD3 (1.00) | SMYD3SOS1KRASADRA2AADRA2B | |
| SCHEMBL19710607 | 0.85 | SMYD3 (1.00) | SMYD3SOS1KRAS | |
| SCHEMBL21489990 | 0.85 | SMYD3 (1.00) | SMYD3SOS1KRAS | |
| SCHEMBL19710447 | 0.81 | SMYD3 (1.00) | SMYD3 | |
| SCHEMBL21489991 | 0.81 | SMYD3 (1.00) | SMYD3 | |
| SCHEMBL19701254 | 0.74 | SMYD3 (0.87) | SMYD3 | |
| SCHEMBL21490203 | 0.74 | SMYD3 (0.87) | SMYD3 | |
| SCHEMBL23575879 | 0.74 | SMYD3 (1.00) | SMYD3SOS1 | |
| SCHEMBL19710453 | 0.74 | SMYD3 (1.00) | SMYD3SOS1 | |
| SCHEMBL3788185 | 0.74 | MEN1 (0.61) | SMYD3SOS1KRASADRA2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885SOS1 740/4885KRAS 474/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SMYD3 2/4885SOS1 504/4885KRAS 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.